🔗 Share this article

While America continues making historic changes to its immunization guidelines, one figure appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations throughout the global health crisis and has concentrated on possible deaths following COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Immunization Program

Public health authorities were set to unveil sweeping revisions to the childhood vaccine schedule in December, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of alignment with much of the global community with no evidence for public health gain. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is listed to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and biologics branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending some pediatric immunization guidelines in the US so as to align more in line with Denmark's approach, a nation with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

To date statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of medication approval.

Doubts Over Expertise

The appointee has little discernible background in pharmaceutical research, regulation or management, which has been typical for former heads of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Previous heads of CBER would “grasp legal statutes and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that former directors who led CBER have had.”

The drug center has an immense portfolio at the FDA, Woodcock emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division clears numerous generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be supervised,” Woodcock explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant management element to the position, which oversees more than 5,000 employees. “It’s a huge management job, if you perform it correctly,” she added.

Agency Reaction and Controversial Programs

When asked about concerns about Høeg’s fitness for the role and whether this selection represents more teamwork among regulatory chiefs on vaccines, a representative said that the “inquiries stem from inaccurate assumptions”.

“Her resume is consistent with the functions of her role,” the official said, pointing to the time Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the agency head's new priority voucher program, a disputed expedited therapy clearance system that apparently worried her predecessors. “How are these drugs being selected for this fast-track system? Who makes the calls?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he stated, “the agency looks to be trending towards laxer rules of all drugs, except for immunizations.”

Established Track Record on Immunizations

Regarding immunizations, Høeg has a more documented, if concerning, track record, some experts have noted. She released a analysis using unverified public submissions to assess the incidence of heart inflammation following COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are more dangerous than they are.

Included in her “wish list” for the incoming federal leadership featured changing rules for novel immunizations and discontinuing “optional” vaccines, she stated after the election on a online show. At the agency, Høeg has allegedly proposed excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the science in a very deceptive, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|